GlassScriptPhysician profile
Leslie A Dork
NPI 1790703361
$7,020.39
in general payments reported to CMS, 2019-2025
27 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,373 · 2022: $2,143 · 2023: $1,204 · 2024: $873 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,501 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,500.57 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,299.28 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Nxstage Medical, INC. | $675.07 | 2021-2025 | Nxstage System One, Liberty Select Cycler |
| Vifor Pharma, INC. | $570.64 | 2021-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $460.07 | 2022-2023 | |
| Novo Nordisk INC | $452.08 | 2021-2025 | Wegovy, Rivfloza, Ozempic |
| Amgen INC. | $448.75 | 2023-2025 | Tavneos, Krystexxa |
| Daiichi Sankyo INC. | $430.84 | 2021-2024 | Injectafer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $254.62 | 2022-2025 | |
| Mozarc Medical US LLC | $238.60 | 2023-2025 | Palindrome, Argyle, Chameleon |
| Glaxosmithkline, LLC. | $226.53 | 2022 | |
| Fresenius USA Marketing, INC. | $199.90 | 2024-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $189.52 | 2021-2025 | Vafseo, Auryxia |
| Alexion Pharmaceuticals, INC. | $187.75 | 2022-2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $164.19 | 2021-2024 | Lupkynis |
| Abbott Laboratories | $153.90 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $151.32 | 2021-2024 | Jynarque |
| Ardelyx, INC. | $146.99 | 2024 | Xphozah 30 Mg, Ibsrela |
| Sanofi-Aventis U.S. LLC | $124.98 | 2022 | |
| Travere Therapeutics, INC. | $123.93 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $99.89 | 2022-2024 | Tarpeyo |
| Lilly USA, LLC | $95.81 | 2022 | |
| Horizon Therapeutics Plc | $86.90 | 2021 | |
| Baxter Healthcare | $78.23 | 2023 | Renal - Pd |
| W. L. Gore & Associates, INC. | $72.51 | 2021 | |
| Genzyme Corporation | $45.05 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $26.12 | 2024 | Crysvita |
| Shield Therapeutics INC | $16.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Dork listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.